Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Magro CM, Kalomeris T, Roberts A. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal. Ann Diagn Pathol. 2023;63:152101.

Nishida J, Cristea S, Bodapati S, Puleo J, Bai G, Patel A, et al. Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression. Proc Natl Acad Sci U S A. 2023;120(49):e2316763120.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.

Baillargeon D, Greenblatt M, Côté M, Nadeau M, Couture C-, Hould F-, et al. Prevalence of Helicobacter pylori Infection in Bariatric Surgery Patients. Obes Surg. 2023;33(7):2132-2138.

Zhang T, Li S, Tan YA, Na JH, Chen Z, Damle P, et al. Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. bioRxiv. 2023.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

Mavragani CP, Kirou KA, Seshan SV, Crow MK. Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford). 2023;62(7):2534-2538.

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Kim JW, McKay RR, Radke MR, Zhao S, Taplin M-, Davis NB, et al. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023;41(4):871-880.